Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
STOCKHOLM, SWEDEN / ACCESSWIRE / February 9, 2024 / Vicore Pharma Holding (STO:VICO)C21 is a potentially transformative therapy for the treatment of idiopathic pulmonary fibrosis (IPF)Vicore to receive USD 10 million upfront and is entitled to up to USD 275 million in milestones in addition to tiered royalty payment.
Vicore Pharma Holding: Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Vicore And Nippon Shinyaku Enter Into An Exclusive License Agreement To Develop And Commercialize C21 In Japan menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.